Human VIP-α: A long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension

Peptides

Volumn 27, Issue 9, 2006, Pages 2271-2275

  Önyüksel, Hayat ^b,c   Séjourné, Florence ^b,c   Suzuki, Hideyuki ^a,d   Rubinstein, Israel ^a,b,d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c University of Illinois at Chicago   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Amphipathic peptide; Conformation; DSPE PEG; Hamster; Microcirculation; Sterically stabilized liposomes; Vasomotor tone

Indexed keywords

LIPOSOME; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ALPHA;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADATION; BLOOD PRESSURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; HAMSTER; MALE; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOCOMPATIBLE MATERIALS; BIODEGRADATION, ENVIRONMENTAL; CRICETINAE; HUMANS; HYPERTENSION; INJECTIONS, INTRAVENOUS; MALE; NANOSTRUCTURES; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA; CRICETINAE;

EID: 33746881443     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.03.003     Document Type: Article

References (31)

1. Chan S.L., and Fiscus R.R. Vasorelaxations induced by calcitonin gene-related peptide, vasoactive intestinal peptide, and acetylcholine in aortic rings of endothelial and inducible nitric oxide synthase-knockout mice. J Cardiovasc Pharmacol 41 (2003) 434-443
2. Cheng Z.J., Vapaatalo H., and Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 11 (2005) RA194-RA205
3. Chien S., Fan F., Lee M.M., and Handley D.A. Effects of arterial pressure on endothelial transport of macromolecules. Biorheology 21 (1984) 631-641
4. Cosentino F., and Volpe M. Hypertension, stroke, and endothelium. Curr Hypertens Res 7 (2005) 68-71
5. Ganea D., Rodriguez R., and Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypepeptide: players in innate and adaptive immunity. Cell Mol Biol 49 (2003) 127-142
6. Gololobov G., Noda Y., Sherman S., Rubinstein I., Baranowska-Kortylewicz J., and Paul S. Stabilization of vasoactive intestinal peptide by lipids. J Pharmacol Exp Ther 285 (1998) 753-758
7. Henning R.J., and Sawmiller D.R. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 49 (2001) 27-37
8. Ignarro L.J., Byrns R.E., Buga G.M., and Wood K.S. Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP. Am J Physiol 253 (1987) H1074-H1082
9. Ikezaki H., Önyüksel H., and Rubinstein I. Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo. Am J Physiol 275 (1998) R588-R595
10. Ikezaki H., Paul S., Alkan-Önyüksel H., Patel M., Gao X.-.P., and Rubinstein I. Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch. Am J Physiol 275 (1998) R56-R62
11. Julius S. Five decades of antihypertensive treatment: the unresolved issues. J Hypertens Suppl 18 (2000) S3-S7
12. Kurjiaka D.T. The conduction of dilation along an arteriole is diminished in the cremaster muscle of hypertensive hamsters. J Vasc Res 41 (2004) 517-524
13. Kurjiaka D.T., Bender S.B., Nye D.D., Wiehler W.B., and Welsh D.G. Hypertension attenuates cell-to-cell communication in hamster retractor muscle feed arteries. Am J Physiol 288 (2005) H861-H870
14. Nandha K.A., Benito-Orfila M.A., Smith D.M., Ghatei M.A., and Bloom S.R. Action of pituitary adenyl cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding. J Endocrinol 129 (1991) 69-73
15. Noda Y., Rodriguez-Sierra J., Liu J., Landers D., Mori A., and Paul S. Partitioning of vasoactive intestinal polypeptide into lipid bilayers. Biochem Biophys Acta 1191 (1994) 324-330
16. Önyüksel H., Ikezaki H., Patel M., and Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm Res 16 (1999) 155-160
17. Önyüksel H., Bodalia B., Sethi V., Dagar S., and Rubinstein I. Surface-active properties of vasoactive intestinal peptide. Peptides 21 (2000) 419-423
18. Plante G.E. Vascular response to stress in health and disease. Metabolism 51 Suppl. 1 (2002) 25-30
19. Puddu P., Puddu G.M., Cravero E., and Muscari A. Different effects of antihypertensive drugs on endothelial dysfunction. Acta Cardiol 59 (2004) 555-564
20. 131I-VIP in rat using gamma camera. Nucl Med Biol 26 (1999) 931-936
21. Rubinstein I., Houmsse M., Davis G., and Vishwanatha J.K. Tissue angiotensin I-converting enzyme activity in spontaneously hypertensive hamsters. Biochem Biophys Res Commun 183 (1992) 1117-1123
22. Rubinstein I., Patel M., Ikezaki H., Dagar S., and Önyüksel H. Conformation and vasoreactivity of VIP in phospholipid micelles: effects of calmodulin. Peptides 20 (1999) 1497-1501
23. Séjourné F., Rubinstein I., Suzuki H., and Alkan-Önyüksel H. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm Res 14 (1997) 362-365
24. Séjourné F., Suzuki H., Alkan-Önyüksel H., Gao X.-p., Ikezaki H., and Rubinstein I. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo. Am J Physiol 273 (1997) R287-R292
25. Sethi V., Önyüksel H., and Rubinstein I. Liposomal vasoactive intestinal peptide. Meth Enzymol 391 (2005) 377-395
26. Suzuki H., Noda Y., Paul S., Gao X.-P., and Rubinstein I. Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilation in vivo. Life Sci 57 (1995) 1451-1457
27. Suzuki H., Gao X.-p., Olopade C.O., and Rubinstein I. Neutral endopeptidase modulates vasoactive intestinal peptide-induced vasodilation in situ. Am J Physiol 271 (1996) R393-R397
28. Suzuki H., Noda Y., Gao X.-p., Séjourné F., Alkan-Önyüksel H., Paul S., et al. Encapsulation of vasoactive intestinal peptide into liposomes restores vasorelaxation in hypertension in situ. Am J Physiol 271 (1996) H282-H287
29. Tedgui A., Merval R., and Esposito B. Albumin transport characteristics of rat aorta in early pahse of hypertension. Circ Res 71 (1992) 932-942
30. Thomas C.L., Artwohl J.E., Suzuki H., Gao X.-p., White E., Saroli A., et al. Initial characterization of hamsters with spontaneous hypertension. Hypertension 30 part 1 (1997) 301-304
31. Ye V.Z., Hodge G., Young J.L., and Duggan K.A. Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension. Eur J Pharmacol 485 (2004) 235-242